Drugs / Tcm cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02704299 | Mar 2016 → Jun 2018 | gastric cancer | Shanghai AbelZeta Ltd. | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05268172 | Dec 2022 → Dec 2024 | pleural neoplasm | Affiliated Hospital of Jiangnan University | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03587285 | Sep 2018 → Jul 2021 | prostate neoplasm | Guangzhou University of Traditional Chinese Medicine | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tcm cells | “TCM cells are the subpopulation of T lymphocytes with key characteristics including high potency and long-term memory of specific immunity.” NCT02704299 ↗ |
| Modality | Cell therapy | “infusion of autologous Tcm cells” NCT03587285 ↗ |
| Route | Intravenous | “Tcm cells administered intravenously on Day 1 and Day 42” NCT03587285 ↗ |